Core Insights - The company reported a total operating revenue of 1,043,768,680.27 yuan for the fiscal year 2025, representing a year-on-year growth of 29.52% [1] - The net profit attributable to the parent company's shareholders reached 272,124,670.05 yuan, showing a significant year-on-year increase of 117.72% [1] Financial Performance - Total operating revenue for 2025: 1,043.77 million yuan, up 29.52% from the previous year [1] - Net profit attributable to shareholders: 272.12 million yuan, an increase of 117.72% year-on-year [1]

Group 1 - The core viewpoint of the article highlights that Spring Medical reported a significant increase in its 2025 annual performance, with operating revenue reaching approximately 1.044 billion yuan, representing a year-on-year increase of 29.52% [1] - The net profit attributable to shareholders of the listed company was approximately 272 million yuan, showing a substantial year-on-year increase of 117.72% [1] - The basic earnings per share were reported at 0.71 yuan, which is an increase of 115.15% compared to the previous year [1] Group 2 - The article also discusses a notable shift in the AI landscape, indicating that China's AI usage has surpassed that of the United States for the first time, leading to a surge in various sectors within the A-share market [1] - A well-known Wall Street analyst commented on how China's computing power path is overturning traditional perceptions, suggesting a transformative impact on the industry [1]

Core Viewpoint - Spring Medical (01858) reported a strong performance for the fiscal year 2025, with total revenue of approximately 1.044 billion yuan, representing a year-on-year growth of 29.52%, and a net profit attributable to shareholders of approximately 272 million yuan, reflecting a significant increase of 117.72% [1] Revenue Growth - The growth in revenue is primarily attributed to the normalization of national procurement for orthopedic consumables, which has led to a steady increase in product sales and an expansion of domestic business scale and market share [1] - The company has successfully leveraged its comprehensive channel coverage and diverse product portfolio to enhance profitability [1] International Expansion - Spring Medical is advancing its international strategy, achieving continuous expansion and breakthroughs in international markets, supported by products that meet international advanced standards in technology and quality [1] - The steady increase in overseas revenue has been a crucial contributor to the overall performance growth of the company [1] Operational Efficiency - The company is focusing on refined operational management and optimizing operational efficiency, which has led to significant improvements in overall operational efficiency and profitability [1] - Through large-scale production, the company has further strengthened its economies of scale, contributing to enhanced operational performance [1]

格隆汇2月27日丨春立医疗(01858.HK)公告， 2025年度业绩快报，公司实现营业总收入人民币10.4亿 元，较上年同期增长29.52%；实现归属于母公司所有者的净利润人民币2.72亿元，较上年同期增长 117.72%。 报告期内，公司产品集采落地后增长潜力持续释放，国际化业务稳步推进，内外协同驱动营收稳健增 长；同时公司持续优化经营管理与资源配置，经营效率与盈利能力进一步提升，共同推动业绩实现良好 增长。 ...

Core Viewpoint - Spring Medical (01858) reported a significant increase in revenue and net profit for the fiscal year 2025, driven by the normalization of national procurement for orthopedic consumables and steady international business expansion [1] Financial Performance - Total revenue for the year reached approximately 1.044 billion yuan, representing a year-on-year growth of 29.52% [1] - Net profit attributable to the parent company was about 272 million yuan, showing a remarkable year-on-year increase of 117.72% [1] - Basic earnings per share stood at 0.71 yuan [1] Business Growth Drivers - The growth in performance is primarily attributed to the steady increase in product sales due to the normalization of national procurement for orthopedic consumables [1] - The company has expanded its domestic business scale and market share, which has contributed to the steady improvement in profitability [1] - Continuous internationalization strategy has led to sustained business expansion in international markets, providing significant support for overall performance growth [1] Operational Efficiency - The company has focused on refined operational management and optimized operational efficiency [1] - Through large-scale production, the company has strengthened its economies of scale, resulting in significant improvements in overall operational efficiency and profitability [1]

北 京 市 春 立 正 達 醫 療 器 械 股 份 有 限 公 司 Beijing Chunlizhengda Medical Instruments Co., Ltd. * 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股 份 代 號：1858） 2025年度業績快報 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部份內容而產生 或因依賴該等內容而引致的任何損失承擔任何責任。 本 公 告 由 北 京 市 春 立 正 達 醫 療 器 械 股 份 有 限 公 司（「本公司」或「公 司」，連 同 其 附 屬 公 司 統 稱「本集團」）根 據 香 港 聯 合 交 易 所 有 限 公 司 證 券 上 市 規 則 第 13.09(2)及13.10B條以及香港法例第571章證券及期貨條例第XIVA部的內幕 消息條文作出。 本公告所載2025年度主要財務數據為初步核算數據，未經會計師事務所審 計，具體數據以公司2025年年度報告為準，提請投資者注意投資風險。 一、 2025年度主要財務數據和指標 ...

公司实现营业总收入 1,043,768,680.27 元，较上年同期增长 29.52%；实现归属于母公司所有者的净利润 272,124,670.05 元，较上年同期增长 117.72%。报告期末，公司总资产 3,659,165,538.06 元，较期初增长 5.58%；归属于母公司的所有者权益 2,985,050,158.61 元，较期初增长 5.86%；归属于母公司所有者的每 股净资产 7.78 元，较期初增长 5.86%。 （二）上表中有关项目增减变动幅度达 30%以上的，增减变动的主要原因报告期内营业利润、利润总 额、归属于母公司所有者的净利润、归属于母公司所有者的扣除非经常性损益的净利润及基本每股收益 较上年同期显著增长，主要原因为： 1、随着骨科耗材国家集采常态化推进，公司依托完善的渠道覆盖网络与丰富的产品体系，产品销量稳 步提升，国内业务规模与市场份额持续扩大，推动盈利水平稳步提升。 2、公司持续推进国际化战略，依托达到国际先进水平的产品技术与质量标准，在国际市场实现了业务 的持续拓展与突破，海外营收稳步提升，为公司整体业绩增长提供重要支撑。 证券之星消息，春立医疗近日即将发布2025年年报，根据 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本公告所载2025年度主要财务数据为初步核算数据，未经会计师事务所审计， 具体数据以公司2025年年度的定期报告为准，提请投资者注意投资风险。 一、2025 年度主要财务数据和指标 单位：元 | 项目 | 本报告期 | 上年同期 | 增减变动幅度 | | --- | --- | --- | --- | | | | | （％） | | 营业总收入 | 1,043,768,680.27 | 805,857,022.19 | 29.52 | | 营业利润 | 301,753,694.59 | 130,714,693.96 | 130.85 | | 利润总额 | 301,220,328.25 | 131,599,169.07 | 128.89 | | 归属于母公司所有者 的净利润 | 272,124,670.05 | 124,988,009.59 | 117.72 | | 归属于母公司所有者 的扣除非经常性损益 | 255,107,825.37 | 94,536,002.40 | 1 ...

Core Viewpoint - The company achieved a total operating revenue of 1.044 billion yuan in 2025, representing a year-on-year growth of 29.52% [1] - The net profit reached 272 million yuan, with a significant year-on-year increase of 117.72% [1] Group 1: Revenue Growth - The company's product collection has led to a sustained release of growth potential [1] - The international business is steadily advancing, contributing to revenue stability [1] Group 2: Operational Efficiency - Continuous optimization of management and resource allocation has enhanced operational efficiency [1] - Improved profitability has collectively driven the company's performance to achieve good growth [1]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 重新提交 致：香港交易及結算所有限公司 1. 股份分類 普通股 股份類別 H 於香港聯交所上市 (註1) 是 證券代號 (如上市) 01858 說明 H股 已發行股份（不包括庫存股份）數目 庫存股份數目 已發行股份總數 上月底結存 95,140,500 0 95,140,500 增加 / 減少 (-) 0 0 本月底結存 95,140,500 0 95,140,500 公司名稱: 北京市春立正達醫療器械股份有限公司 呈交日期: 2026年2月26日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01858 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | ...